Now showing items 1-5 of 5
Host markers in Quantiferon supernatants differentiate active TB from latent TB infection : preliminary report
(BioMed Central, 2009-05)
Background: Interferon gamma release assays, including the QuantiFERON® TB Gold In Tube (QFT) have been shown to be accurate in diagnosing Mycobacterium tuberculosis infection. These assays however, do not discriminate ...
A metabolic biosignature of early response to anti-tuberculosis treatment
(BioMed Central, 2014-01)
Background The successful treatment of tuberculosis (TB) requires long-term multidrug chemotherapy. Clinical trials to evaluate new drugs and regimens for TB treatment are protracted due to the slow clearance ...
Epigenetics and proteomics join transcriptomics in the quest for tuberculosis biomarkers
(American Society for Microbiology, 2015-09-15)
An estimated one-third of the world’s population is currently latently infected with Mycobacterium tuberculosis. Latent M. tuberculosis infection (LTBI) progresses into active tuberculosis (TB) disease in ~5 to 10% of ...
Bacterial loads measured by the Xpert MTB/RIF assay as markers of culture conversion and bacteriological cure in pulmonary TB
(Public Library of Science, 2016)
Introduction: Biomarkers are needed to monitor tuberculosis (TB) treatment and predict treatment outcomes. We evaluated the Xpert MTB/RIF (Xpert) assay as a biomarker for TB treatment during and at the end of the 24 ...
Changes in host immune–endocrine relationships during tuberculosis treatment in patients with cured and failed treatment outcomes
(Frontiers Media, 2017)
A bidirectional communication between the immune and endocrine systems exists and facilitates optimum responses in the host during infections. This is in part achieved through changes in secretion patterns of hypothalamic ...